Systematic review of 6 studies (2,040 patients with superficial vein thrombosis; 602 on DOACs): DOACs had VTE prevention comparable to fondaparinux (RR 0.93) and, in 4 studies, less major or clinically relevant bleeding than fondaparinux or LMWH (RR 0.35).
Meta-analysisn = 2,040
Boccatonda et al. Efficacy and Safety of DOACs for the Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis